Advance Search

The preventive effect of bismuth and vitamin E combination on cisplatin hepatotoxicity in cancer patients

Muhanad Salah Mowlood
Department of Biochemistry, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
Keywords:
Copyright and Licensing:

Copyright (c) 2012 Muhanad Salah Mowlood (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Share:
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Background and objectives: The objective of this study was to explore the optimal combination of agents with their doses used along with cisplatin for the protection of hepatotoxicity.

Methods: This experiment was carried out on a patients suffering from different solid types of tumor divided into two groups: cisplatin group receiving cisplatin in a dose of 90 mg/ m² body surface area(BSA) and the therapy group receiving cisplatin in a dose of 90 mg/m² BSA and bismuth subcitrate (200mg/day) with vitamin E (400mg/day). Ten healthy subjects were taken as a control group.Total serum bilirubin (TSB), serum glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT) and alkaline phosphatase (ALP) were tested for the assessments of liver function.

Results: The level of TSB, GPT, GOT and ALP in healthy subjects did not changed significantly with respect to baseline value along the entire period of the study ; while cisplatin group showed a sustain and significant elevation in TSB, GPT, GOT and ALP level in comparison with baseline along the entire period of the study, P<0.05. Meanwhile, the hepatotoxic effect of cisplatin was shown to be slightly but however significantly decreased in patients received bismuth-vitamin E therapy (P<0.05) along the entire period of the study.

Conclusion: Bismuth and vitamin E combination play a beneficial role for prevention of cisplatin hepatotoxicity. The potentiated actions for prevention of cisplatin hepatotoxicity could be achieved via combined use of these agents.

pdf
pdf

Metrics

Metrics Loading ...

References

  1. Ekborn A, LindbergA, Laurell G,Wallin I, Eksborg S, Ehrsson H Ototoxicity,nephrotoxicity and pharmacokinetics of cisplatin and its Monohydrated complex in the 1guinea pig. Cancer Chemother Pharmacol 2003;51:36–42
  2. Iraz M, KalciogluMT, Kizilay A, Karatas E. Amino guanidine prevents ototoxicity induced by ciplatin in rats. Ann Clin Lab Sci 2005;35(3):329–35.
  3. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007;334(2):115–24.
  4. Liao YJ, Tang H, Jin YP. Study of toxic effects on hearing, kidney and liver of mice induced by anticancer agent of cisplatin and their mechanisms.Chin Pharmacol Bull 2004;20(1):82–5.
  5. Hong KO, Hwang JK, Park KK, Kim SH. Phosphorylation of c-Jun N-terminal Kinases (JNKs) is involved in the preventive effect of Xanthorrhizol on cisplatin-induced hepatotoxicity. ArchToxicol 2005;79(4):231–6.
  6. Pratibha R, Sameer R, Rataboli PV, Bhiwgade DA, Dhume CY. Enzymatic studies of cisplatin induced oxidative stress in hepatic tissue of rats. Eur J Pharmacol 2006;532(3):290–3.
  7. Iseri S, Ercan F, Gedik N, Yuksel M, Alican I. Simvastatin attenuates cisplatin-induced kidney and liver damage in rats. Toxicology 2007;230(2- 3):256–64.
  8. Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the Nephrotoxicity of cisplatin and other platinum compounds: a reviewof some recent research. Food Chem Toxicol 2006;44(8):1173–83.
  9. 9.Blakley BW, Cohen JI, Doolittle ND, Muldoon LL, Campbell KC, Dickey DT, et al. Strategies for prevention of toxicity caused by platinum-based chemotherapy. Laryngoscope 2002;112(11):1997– 2001.
  10. Kim SH, Hong KO, Hwang JK, Park KK. Xanthor rhizol has a Potential to attenuate the high dose cisplatin-induced nephrotoxicity in mice. Food Chem Toxicol 2005;43(1):117–22.
  11. Ramesh G, Reeves WB.TNF-alpha mediates chemokine and Cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Inves 2002;110(6):835–42.
  12. Xiao T, Choudhary S, Zhang W, Ansari NH, Salahudeen A. Possible involvement of oxidative stress in cisplatin-induced apoptosis in LLC-PK1 cells. J Toxicol Environ Health A 2003;66(5):469–79.
  13. Koc A, Duru M, Ciralik H, Akcan R, Sogut S. Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats. Mol Cell Biochem 2005;278(1–2):79–84.
  14. Iraz M, Ozerol E, Gulec M, Tasdemir S, Idiz N, Fadillioglu E, et al. Protective effect of caffeic acid phenethyl ester (CAPE) administration on cisplatin-induced oxidative damage to liver in rat. Cell Biochem Funct 2006;24(4):357– 61.
  15. Disilvestro, R. A., Liu, J., and Klaassen, C. D. Res. Commun. Mol. Pathol. Pharmacol. 1996; 93, 163–170
  16. Naganuma, A., Satoh, M., and Imura, N. Cancer Res. 1987; 47, 983–987
  17. Satoh, M., Aoki, Y., and Tohyama, C. Cancer Chemother. Pharmacol.1977; 40, 358–362.
  18. Antunes, L. M. G., Darin, J. D. C., and M. L. P. Bianchi. Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol. Res. 2000; 41, 405-411. 20.Antunes, L. M. G., Darin, J. D. C., and M. L. P. Bianchi. Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol. Res. 2001; 43, 145-150.
  19. Antunes, L. M. G., Darin, J. D. C., and M. L. P. Bianchi. Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol. Res. 2001; 43, 145-150.
  20. Caffrey, P. B., and G. D. Frenkel. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo. Cancer Chemother. Pharmacol. 2000; 46, 74-78
  21. Naziroğlu, M., Karaoglu, A., and A. O. Askoy. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 2004; 195, 221-230.
  22. Leonetti C, Biroccio A, Gabellini C, Scarsella M, Maresca V, Flori E, et al. Alpha-tocopherol protects against cisplatin-induced toxicity Without interfering with antitumor efficacy. Int J Cancer 2003;104:243–50.
  23. Satoh M, Shimada A, Zhang B, Tohyama C. Renal toxicity caused By cisplatinum in glutathione-depleted metallothionein-null mice. Biochem Pharmacol 2000;60(11):1729–34.
  24. Hosokawa O, Okabe M, Saito S, Saito T, Kurasaki M. Protective role of metallothionein on DNA damage in rat kidney caused by cisdiamminedichloroplatinum. Pharmacol Toxicol 2000;86(6):276–82.
  25. .Bakka. A.. Endresen, L.. Johnsen. A. B. S.. Edminson. P. D.. and Rugstad. H. E. Resistance against ns-diamminedichloroplatinum in cultured cells with a high content of metallothionein. Toxicol. Appi. Pharmacol.. 61: 215-226. 1981.
  26. Kasahara, K.. Fujiwara. Y, Nishino, K.. Ohmori. T.. Sugimoto. Y.Komiya. K. Matuda, T., and Saijor, N. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res.1991; 5: 323- 3242.
  27. Zhang K, Chew M, Yang EB, Wong KP, Mack P. Modulation of Cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms. Mol Pharmacol 2001;59(4):837 –43.
  28. Ikeda K, Miura K, Himeno S, Imura N, Naganuma A. Glutathione Content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum. Mol Cell Biochem 2001;219(1–2):51–6.
  29. Cherian MG, Howell SB, Imura N, Klaassen CD, Koropatnick J,Lazo JS,et al. Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol 1994;126(1):1–5.
  30. Satoh M, Cherian MG, Imura N, Shimizu H. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. CancerRes1994;54(20):5255–7.
  31. Naganuma, A.. Satoh. M.. and Imura. N. Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice. Cancer Res.1987; 47: 983-987.
  32. Kondo. Y. Satoh, M.. Imura. N.. and Akimoto. M. Effect of bismuth nitrate given in combination with cis-diamminedichloroplatinum(ll) on the antitumor activity and renal toxicity of the latter in nude mice inoculated with human bladder tumor. Cancer Chemother Pharmacol.1991; 29: 19-23.
  33. Satoh. M.. Naganuma. A., and Imura. N. Metallothionein induction prevents toxic side effects of cisplatin and Adriamycin used in combination. Cancer Chem. Pharmacol.1988; 21: 176-178.
  34. Satoh, M., Naganuma. A., and Imura. N. Involvement of cardiac metallothionein in prevention of Adriamycin induced lipid peroxidation in the heart. Toxicology, 53:231-237.
  35. Imura. N.. Satoh. M.. and Naganuma. A. Possible application of metallothionein in cancer therapy. In: C. D. Klaassen and K. T. Suzuki (eds.). Metallothionein in Biology and Medicine, Boca Raton. FL: CRC Press, 1992: 375-382.
  36. Satomi. N.. Sakurai. A.. Haranaka. R., and Haranaka. K. Preventive effects ofseveral chemicals against lethality of recombinant human tumor necrosis factor. J. Biol. Response Modif.1988, 7: 54-64
  37. Satoh. M.. Miura. N., Naganuma. A.. Matsuzaki. N.. Kawamura. E.,and Imura. N. Prevention of adverse effects of "y-ray irradiation by metallothionein induction by bismuth subnitrate in mice. Eur. J. Cancer Clin. Oncol.1989 25: 1727-1731.
  38. Naganuma. A., Satoh. M.. and Imura. N. Specific reduction of toxic side effects of Adriamycin by induction of metallothionein in mice. Jpn. J. Cancer Res.1988, 79:406-411
  39. Zicca, A., Cafaggi, S., Mariggio, M. A., Vannozzi, M. O., Ottone, M., Bocchini, V., Caviglioli, G., and M. Viale. Reduction of cisplatin hepatotoxicity by procainamide hydrochloride in rats. Eur. J. Pharmacol. 2004; 442, 265-272.
  40. Koc, A., Duru, M., Ciralik, H., Akcan, R., and S. Sogut. Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats. Mol. Cell Biochem. 2005; 278, 79-84.
  41. Mansour, H. H., Hafez, F. H., and N. M. Fahmy. Silymarin modulates cisplatin-induced oxidative stress and hepatotoxicity in rats. J. Biochem. Mol. Biol. 2006; 39,656-661.
  42. Pratibha, R., Sameer, R., Rataboli, P. V., Bhiwgade, D. A., and C. Y. Dhume. Enzymatic studies of cisplatin-induced oxidative stress in hepatic tissueof rats. Eur. J. Pharmacol. 2006; 532, 290-293.
  43. Antunes, L. M. G., Darin, J. D. C., and M. L. P. Bianchi. Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependant study. Pharmacol. Res. 2000; 41, 405-411.
  44. Jordan, P., and M. Carmo-Fonseca. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol. Life Sci. 2000; 57, 1229–1235.
  45. Atasayar, S., Gurer-Orhan, H., Orhan, H., Gurel, B., Girgin, G., and H. Ozguneş. Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats. Exp. Toxicol. Pathol.2009; 61, 23-32.
  46. Antunes, L. M. G., Darin, J. D. C., and M. L. P. Bianchi. Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol. Res. 2001; 43, 145-150.
  47. Naziroğlu, M., Karaoglu, A., and A. O. Askoy (2004).Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 2004; 195, 221-230.
  48. Halliwell, B., and J. M. C. Gutteridge. Free Radicals in Biology and Medicine, 4rd Ed. Oxford University Press, New York. 2007.
  49. Spallhoz, J. E. On the nature of selenium toxicity and carcinostatic activity. Free Radic. Biol. Med. 1994; 17,45-64.
How to Cite
Mowlood, M. S. (2012). The preventive effect of bismuth and vitamin E combination on cisplatin hepatotoxicity in cancer patients. Zanco Journal of Medical Sciences (Zanco J Med Sci), 16(1), 31–39. https://doi.org/10.15218/zjms.2012.0006

Send mail to Author

Send Cancel